Young Min Choi

Relations between interleukin-1, its receptor antagonist gene polymorphism, and bone mineral density in postmenopausal Korean women

We investigated the relation between polymorphisms in the interleukin-1(IL-1) and IL-1 receptor antagonist (IL-1ra) gene, and bone mineral density (BMD) in postmenopausal Korean women. The IL-1α C−889T polymorphism, and IL-1β C−511T polymorphism were examined by restriction fragment length polymorphism, and 86-bp variable number tandem repeat polymorphism in the IL-1ra gene was analyzed by the polymerase chain reaction and electrophoresis in 202 postmenopausal Korean women. Serum osteocalcin, and C-telopeptide of type I collagen were measured using a radioimmunoassay and enzyme-linked immunosorbent assay, respectively. BMD at the lumbar spine and proximal femur was measured by dual-energy X-ray absorptiometer. No significant differences in BMD or in serum bone markers levels were noted across the IL-1α or IL-1β genotype. There were no significant differences in the distribution of IL-1α or IL-1β genotype according to the status of bone mass. BMD in women carrying the A2 allele of the IL-1ra gene was significantly lower than those without this allele, and the A2 allele was more frequent in osteoporotic women than in normal women. These data suggest that IL-1ra gene VNTR polymorphism is a genetic factor that may affect BMD in Korean women.

Relationships between the insulin-like growth factor I (IGF-I) receptor gene G3174A polymorphism, serum IGF-I levels, and bone mineral density in postmenopausal Korean women

We investigated the relationships between the IGF-I receptor gene G3174A polymorphism, serum IGF-I levels, and bone mineral density (BMD) in postmenopausal Korean women. The IGF-I receptor gene G3174A polymorphism was analyzed in 367 postmenopausal Korean women. Serum levels of IGF-I, bone turnover markers (osteocalcin, bone alkaline phosphatase, carboxy-terminal cross-linking telopeptide of type I collagen), and BMD at the lumbar spine and proximal femur were measured. The frequencies of the AA, GA, and GG genotypes were 10.9%, 44.1%, and 45.0%, respectively. BMD at the lumbar spine was significantly higher for the AA genotype than the other genotypes and showed an A allelic dose effect; however, no significant differences in BMD were observed at the proximal femur with respect to genotype. No differences were noted between the three genotypes in terms of serum levels of IGF-I or bone turnover markers. Women with low BMD showed a lower prevalence of the AA genotype and A allele than age-matched women with normal BMD. Women with the AA genotype were found to have about half the risk of a low BMD than women with other genotypes. In conclusion, IGF-I receptor gene G3174A polymorphism is associated with lumbar spine BMD in postmenopausal Korean women.

A successful live birth with in vitro fertilization and thawed embryo transfer after conservative treatment of recurrent endometrial cancer

Abstract Estrogen-dependent early stage endometrial cancer is relatively common in young women of reproductive age. The standard treatment is hysterectomy and bilateral salpingo-oophorectomy (BSO), even in early stage well-differentiated endometrial cancer patients. This surgical option results in permanent loss of fertility. There have been some reports of live births using in vitro fertilization after conservative management of endometrial cancer with high-dose progestin for the purpose of fertility preservation. However, most were not recurrent cases and pregnancy was achieved through conventional in vitro fertilization, which usually raises serum estradiol levels and may lead to the recurrence of endometrial cancer. To date, it is hard to find a case that can be referred for any possible different approach needed for the patients who experience recurrence. Here we report a successful live birth with in vitro fertilization using letrozole to maintain physiological levels of estradiol, and subsequent thawed embryo transfer after elective cryopreservation of embryos in a patient with recurrent endometrial cancer. There has been no evidence of disease recurrence at one year after delivery.

Feature of amenorrhea in postoperative tamoxifen users with breast cancer

Objective Tamoxifen has been used to prevent the recurrence of breast cancer. However, tamoxifen-users frequently experience amenorrhea and it can be confused from that caused by other hormonal abnormalities. In amenorrheic patients without breast cancer, clinicians usually measure the sex hormone levels that are known to be associated with ovarian or menstrual function. This study aimed to investigate the feature of female sex hormones in premenopausal breast cancer patients undergoing tamoxifen treatment. Methods The medical records of fifty-nine premenopausal breast cancer patients who underwent tamoxifen treatment were reviewed retrospectively. The study population consisted of amenorrheic patients (n=36) and patients with menstruation (n=23). Serum hormone levels were measured either specifically between cycle days 2 and 5 in menstruating patients or at any time in amenorrheic participants. Results Serum levels of lutenizing hormone and estradiol were not statistically different according to the presence of menstruation. Serum follicle stimulating hormone level was significantly higher in amenorrheic patients (8.1±5.7 mIU/mL) than those in menstruating subjects (5.1±2.2 mIU/mL) (p=0.01). Serum concentration of thyroid stimulating hormone was lower in patients with amenorrhea (1.5±0.9 vs. 2.3±2.2 μIU/mL, p=0.04), although the prevalence of hypo- or hyperthyroidism was not different according to the pattern of menstruation. Conclusion Menstruation status and hormone levels can be influenced by tamoxifen use in reproductive age breast cancer patients. Physicians should be attentive to the alteration of pituitary hormone levels in addition to sex steroid hormones in this population.

BMP2 Induces Direct Differentiation into Cardiomyocytes from Human Embryonic Stem Cells during Short-Tem Culture In Vitro

Abstract 367 presented at Poster Session: Basic Parturition/Prematurity II (Friday, 3/26/2010, 10:00 AM - 12:00 PM)Plenary Session: Presidents New Investigator (Thursday, 3/25/2010, 9:00AM 10:00 AM) Scientific Abstracts